Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,184.00    -14.00 (-0.64%)
Bid:
2,182.00
Ask:
2,186.00
Spread: 4.00 (0.183%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
 



 

For immediate release 4 January 2012

 

 

 

 

 

 

 

GENUS plc

("Genus" or "the Company")

 

Senior Management Changes

 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

 

Karim Bitar, Chief Executive, commented:

 

 "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

 

 

 

 

 

For further information please contact:

 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.com 

 

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBJMRTMBJMBLT
Date   Source Headline
23rd Sep 20209:35 amRNSDirector/PDMR Shareholding
16th Sep 202012:16 pmRNSDirector/PDMR Shareholding
15th Sep 20205:52 pmRNSDirector/PDMR Shareholding
9th Sep 202012:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
8th Sep 20203:16 pmRNSApplication for Additional Listing
8th Sep 20207:00 amRNSPreliminary Results
1st Sep 20201:03 pmRNSTotal Voting Rights
3rd Aug 20204:15 pmRNSBlock listing Interim Review
1st Jul 202010:41 amRNSTotal Voting Rights
30th Jun 20203:45 pmRNSNOTIFICATION OF MAJOR HOLDINGS
29th Jun 20207:00 amRNSDirectorate Appointment
14th May 20206:23 pmRNSApplication for Block Listing
1st May 20203:04 pmRNSTotal Voting Rights
30th Apr 202010:24 amRNSCompliance with LR 9.2.6ER(1)
22nd Apr 20205:47 pmRNSDirector/PDMR Shareholding
21st Apr 202012:14 pmRNSNotification of Major Holdings
20th Apr 20209:28 amRNSDirector/PDMR Shareholding
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:52 pmRNSTotal Voting Rights
27th Feb 20207:00 amRNSInterim Results
26th Feb 202012:44 pmRNSNOTIFICATION OF MAJOR HOLDINGS
17th Feb 20205:27 pmRNSNotification of Major Holdings
7th Feb 20209:03 amRNSNotification of Major Holdings
3rd Feb 202010:51 amRNSBlock listing Interim Review
23rd Jan 20203:52 pmRNSNotification of Major Holdings
2nd Jan 202010:02 amRNSTotal Voting Rights
12th Dec 20192:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Dec 20194:45 pmRNSTotal Voting Rights
20th Nov 20197:00 amRNSAppointment of Chief Financial Officer
15th Nov 20196:18 pmRNSDirector/PDMR Shareholding
14th Nov 20191:23 pmRNSResult of AGM
14th Nov 20197:00 amRNSAGM TRADING UPDATE
1st Nov 201912:05 pmRNSTotal Voting Rights
14th Oct 20198:00 amRNSAnnual Report and Annual General Meeting
10th Oct 20193:30 pmRNSDirector/PDMR Shareholding
3rd Oct 20193:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Oct 20193:38 pmRNSNotification of Major Holdings
1st Oct 20195:23 pmRNSTotal Voting Rights
20th Sep 201912:38 pmRNSDirector/PDMR Shareholding
18th Sep 20196:09 pmRNSDirector/PDMR Shareholding
17th Sep 20191:24 pmRNSDirector/PDMR Shareholding
12th Sep 20192:59 pmRNSDirector/PDMR Shareholding
11th Sep 20198:02 amRNSCORRECTION: Outcome of IntelliGen Litigation
11th Sep 20197:00 amRNSOutcome of latest IntelliGen Litigation
10th Sep 20197:00 amRNSOUTCOME IN LATEST INTELLIGEN LITIGATION
5th Sep 20197:00 amRNSPreliminary Results
22nd Aug 20197:00 amRNSAppointment of Chief Executive Officer
1st Aug 20195:49 pmRNSBlock listing Interim Review
1st Aug 20195:46 pmRNSTotal Voting Rights
30th Jul 201912:12 pmRNSNOTIFICATION OF MAJOR HOLDINGS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.